### Empowering TB-Affected People to Support Their Treatment & Care During COVID-19

Patient Basic Details

Presenters: Andrew Cross, CEO Everwell Kelly M. Collins, CEO SureAdhere

17 June 2020

Everwell sureAdhere

🛛 wisepill 💮

everwell.org | sureadhere.com | wisepill.com

## **PROBLEM STATEMENT**



TB is curable, however...

Lack of support for TB-affected people to adhere to a burdensome medication regime with personalized counseling can lead to increased costs, mortality, and emergence of drug resistance




Challenges to supporting adherence

- Side-effects, ADR
- Dosage timing and amount
- Travel burden/ costs
- Timely refills
- Counseling and support
- Differentiated care

#### IMPORTANCE OF ADHERING TO TB MEDICATIONS

Variable	Number of unfavorable outcome number of study participants (%			HR (95	5% CI)	
Adherence						
100%	238/1,348 (18)		<b>.</b>			Reference
>90 and <100%	64/288 (22)					1.4 (1.0-1.9)
≤90%	15/32 (47)					5.7 (3.3-9.9)
Month 2 culture status						
Negative	212/1,357 (16)					Reference
Positive	105/311 (34)		<b>—</b>	-		2.2 (1.7-2.9)
Sex						
Female	64/492 (13)		<b>•</b>			Reference
Male	253/1,176 (22)		<b>⊢−−⊞−−−1</b>			1.6 (1.2-2.1)
Smear grade						
Smear negative or 1+	53/388 (14)		•			Reference
Smear 2+	72/430 (17)	<b>—</b>	┼╼╌┥			1.2 (0.8–1.7)
Smear 3+	192/850 (23)		⊢-∎1			1.6 (1.2-2.3)
HIV status						
Negative	270/1,463 (18)					Reference
Positive	47/205 (23)		<b>H</b>			1.5 (1.1–2.0)
BMI (per 5 kg m <sup>-2</sup> decreas	se) <sup>b</sup>		┝╾╋╾┥			1.4 (1.1–1.7)
Age (per 10-year increase	e) b					1.1 (1.0–1.2)
	Н	<u>⊢</u>	<u> </u>	I		
	0.01	0.5	1.0 2.0	5.0	10.0	
Rada Savic et al, Nature 201	.8 Everwel	sureAdhere	wisepill 阙			

#### EMPOWERING TB-AFFECTED PEOPLE, PROMOTING CHOICE AND ABOVE ALL ENGAGEMENT AND SUPPORT DURING TREATMENT



COVID environment makes it even more challenging to engage, and travel or physically meeting between people and providers a barrier

#### 99DOTS





#### VIDEO OBSERVED THERAPY (VOT)





#### evriMED ELECTRONIC PILLBOXES










# Unified platform with many options for treatment support

Support for Tuberculosis, HIV, COVID, and mental health in various settings






#### PLATFORM EXPERIENCE FOR PROVIDERS




Patient Basic	Details
First Name*	
This field is required	
Surname*	
Address	
This field is required	
Gender	() Male
Female	Transgender
Adherence Technology*	
○ VOT ○ 99DOTS	







#### PLATFORM EXPERIENCE FOR PROVIDERS




#### PLATFORM EXPERIENCE FOR PROVIDERS



TB information page




Adherence Calendar



Home Page



#### DAT-SUPPORTED ENGAGEMENT IN PROGRAMMATIC SETTINGS



#### HOW DATS CAN SUPPORT TB-AFFECTED PEOPLE

• <u>Autonomy</u>: Person can decide where/when to take their medications

 <u>Differentiated Care</u>: Person may receive individualized information, prompted to take action pertaining to their treatment, and/or access treatment information via patient app or SMS.

• <u>Real-time connection with provider</u>: Person can communicate directly with health care worker using SMS or mobile application









#### BENEFITS OF DATs TO PROVIDERS

#### **Clinic / Provider Level**


- Automated alerts and reporting prompts fast action
- Individual and clinic adherence data helps structure treatment decisions and counseling in real-time
- Aggregate data allows for rapid triage of people under their care, helping providers to quickly determine those who need more support

#### National / Sub-National Levels

 National TB Program coordinators can identify trends and/or compare treatment outcomes between districts or health facilities and rapidly to identify disparities in health outcomes







#### WHO SUPPORT FOR DATS

#### ) TREATMENT OF TUBERCULOSIS 🧕

Guidelines for treatment of drug-susceptible tuberculosis and patient care

2017 UPDATE

World Health Organization The evidence also showed that when patients receiving treatment adherence interventions (e.g. different combinations of patient education, staff education, material support, psychological support, tracer and use of medication monitor) in conjunction with DOT or SAT, the treatment outcomes were significantly improved compared to DOT or SAT alone."

WHO DS-TB Guidelines, 2017

**4** As treatment supervision alone is not likely to be sufficient to ensure good TB treatment outcomes, additional treatment adherence interventions need to be provided."

WHO DS-TB Guidelines, 2017 HANDBOOK FOR THE USE OF DIGITAL TECHNOLOGIES TO SUPPORT TUBERCULOSIS MEDICATION ADHERENCE.



## SCALE UP OF DATs IN TB CARE

6 COUNTRIES ACROSS THE GLOBE



## **ONGOING DAT EVALUATIONS**



20 PROJECTS IN 16 COUNTRIES. APPROXIMATELY 13,000 TB-AFFECTED PEOPLE - DS,



#### BARRIERS AND CHALLENGES TO DAT IMPLEMENTATIONS

#### **TB-Affected People**


- Access
- Burden vs. perceived benefits
- Appropriateness

#### Clinic / Provider

- Capacity building, supplement workflows
- Access to devices, connectivity, power
- Ability to act based on information obtained

#### Program/NTP

- Capacity building and programmatic support
- Data Hosting (in-country vs. cloud)
- Integration with legacy systems



#### PARTNERS AND COLLABORATORS - THANK YOU!



Contact us for more information, evidence, or experiences with DATs in various

settings! Andrew Cross	Kelly Collins	Lloyd Marshal
andrew@everwell.org	kelly.collins@sureadhere.com	lloyd@wisepill.com
99DOTS and Hub	VOT and deployment experience	evriMED device procurement

